A
Azeem Sharda
Researcher at Harvard University
Publications - 12
Citations - 472
Azeem Sharda is an academic researcher from Harvard University. The author has contributed to research in topics: Bone marrow & Progenitor cell. The author has an hindex of 5, co-authored 10 publications receiving 189 citations.
Papers
More filters
Journal ArticleDOI
Lipid availability determines fate of skeletal progenitor cells via SOX9
Nick van Gastel,Steve Stegen,Guy Eelen,Sandra Schoors,Aurélie Carlier,Veerle W. Daniels,Veerle W. Daniels,Ninib Baryawno,Dariusz Przybylski,Maarten Depypere,Pieter-Jan Stiers,Dennis Lambrechts,Riet Van Looveren,Sophie Torrekens,Azeem Sharda,Patrizia Agostinis,Diether Lambrechts,Frederik Maes,Johan Swinnen,Liesbet Geris,Liesbet Geris,Hans Van Oosterwyck,Bernard Thienpont,Peter Carmeliet,David T. Scadden,Geert Carmeliet +25 more
TL;DR: It is shown that obstruction of vascular invasion during bone healing favours chondrogenic over osteogenic differentiation of skeletal progenitor cells, driven by a decreased availability of extracellular lipids.
Journal ArticleDOI
An injectable bone marrow–like scaffold enhances T cell immunity after hematopoietic stem cell transplantation
Nisarg J. Shah,Angelo S. Mao,Angelo S. Mao,Ting-Yu Shih,Ting-Yu Shih,Matthew D Kerr,Matthew D Kerr,Matthew D Kerr,Azeem Sharda,Theresa M. Raimondo,Theresa M. Raimondo,James C. Weaver,Vladimir Vrbanac,Vladimir Vrbanac,Maud Deruaz,Maud Deruaz,Andrew M. Tager,Andrew M. Tager,David J. Mooney,David J. Mooney,David T. Scadden +20 more
TL;DR: A biomaterial-based scaffold that mimics features of T cell lymphopoiesis in the bone marrow improves T cell regeneration after hematopoietic stem cell transplantation and may provide an off-the-shelf approach for enhancing T cell Regeneration and mitigating graft-versus-host disease in HSCT.
Journal ArticleDOI
A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia.
Nisarg J. Shah,Alexander J. Najibi,Alexander J. Najibi,Ting-Yu Shih,Ting-Yu Shih,Angelo S. Mao,Angelo S. Mao,Azeem Sharda,David T. Scadden,David J. Mooney,David J. Mooney +10 more
TL;DR: It is shown that a macroporous-biomaterial vaccine that delivers the cytokine granulocyte–macrophage colony-stimulating factor, the Toll-like-receptor-9 agonist cytosine–guanosine oligodeoxynucleotide and one or multiple leukaemia antigens induces local immune-cell infiltration and activated dendritic cells, evoking a potent anti-AML response.
Journal ArticleDOI
Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance
Nick van Gastel,Jessica B. Spinelli,Azeem Sharda,Amir Schajnovitz,Ninib Baryawno,Ninib Baryawno,Catherine Rhee,Toshihiko Oki,Eliane Grace,Heather J. Soled,Jelena Milosevic,David B. Sykes,Peggy P. Hsu,Peggy P. Hsu,Matthew G. Vander Heiden,Matthew G. Vander Heiden,Charles Vidoudez,Sunia A. Trauger,Marcia C. Haigis,David T. Scadden +19 more
TL;DR: It is proposed that timed cell-intrinsic or niche-focused metabolic disruption can exploit a transient vulnerability and induce metabolic collapse in cancer cells to overcome chemoresistance.
Journal ArticleDOI
Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
Rushdia Z. Yusuf,Borja Saez,Azeem Sharda,Nick van Gastel,Vionnie W.C. Yu,Ninib Baryawno,Elizabeth W. Scadden,Sanket S. Acharya,Shrikanta Chattophadhyay,Cherrie Huang,Vasanthi Viswanathan,Dana S'aulis,Julien Cobert,David B. Sykes,Mark A. Keibler,Sudeshna Das,John N. Hutchinson,Michael Churchill,Siddhartha Mukherjee,Dongjun Lee,Francois Mercier,John G. Doench,Lars Bullinger,David J. Logan,Stuart L. Schreiber,Gregory Stephanopoulos,William B. Rizzo,David T. Scadden +27 more
TL;DR: Inhibiting Aldh3a2 provides a therapeutic opportunity and a unique synthetic lethality to exploit the distinctive metabolic state of malignant cells in acute myeloid leukemia.